Condition: Prostate Cancer Castration-resistant Prostate Cancer · Breast Cancer · Colo-rectal Cancer · Sponsor: MBrace Therapeutics
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| START, Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START, Astera | East Brunswick, New Jersey, United States | Recruiting |
| NEXT, Dallas | Irving, Texas, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| START, Mountain Region | West Valley City, Utah, United States | Recruiting |
| NEXT, Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07145255